featured
Efficacy, Safety, and Pharmacokinetics of a Pertuzumab Biosimilar vs Pertuzumab in HER2+ MBC in India
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer
Clin. Breast Cancer 2024 Jul 10;[EPub Ahead of Print], R Kothari, M Doshi, PK Chaithanya, S Ct, A Kumar, KM Mallavarapu, R Nagarkar, V Mahobia, N Bhatt, KL Priyadarshini, A Gogia, T Maksud, S Prasad, K Velavan, R L K, P Ss, V Talreja, K Kalra, B Nemade, AG Dastidar, T Gupta, T Patil, S Bondarde, P Patel, S Gupta, G Biswas, M Vaghela, P Mahato, H Parekh, M Kalloli, R Shetty, G Prakash, A Goel, S Mandal, T Choudhury, M Jain, C Goswami, YK H M, KK Mukherjee, R Shrivastava, D ParmarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.